<h1>AstraZeneca Pharma India Records 30% Revenue Growth in Q1 FY2026-27, Driven by Oncology and Strategic Initiatives</h1>
AstraZeneca Pharma India Limited announced strong financial results for the quarter ended June 30, 2026, reporting a 30% increase in total revenue from operations to INR 6,828 Mn. The performance was attributed to continued momentum across core therapy areas including Oncology, Biopharmaceuticals (CVRM and R&I), and Rare Diseases, reflecting the company's focused strategy on improving patient outcomes in India.
The company strengthened its portfolio during the quarter through key regulatory approvals, advanced strategic partnerships, and targeted capability-building initiatives aimed at addressing unmet medical needs.
Financial Performance Snapshot
Financial results for the quarter are detailed below (all values in INR Mn):
| Financial Metric | Value |
|---|---|
| Total Revenue from Operations | 6,828 |
| Profit before exceptional item and tax | 510 |
| Profit after exceptional item and tax | 507 |
The performance across therapeutic areas showed notable movement compared to the previous year:
| Therapeutic Area (TA) | Q1 2026-27 Absolute Numbers | Growth vs. Q1 2025-26 |
|---|---|---|
| Oncology | 4,649 | 26% |
| Biopharmaceuticals (CVRM, R&I and V&I) | 1,619 | 36% |
| Rare Diseases | 144 | 35% |
Regulatory Approvals and Strategic Focus
The company secured several regulatory approvals that expanded its offerings in critical areas. Key milestones include:
- Acalabrutinib for CLL/SLL: Regulatory approval was granted for acalabrutinib in combination with venetoclax or obinutuzumab for the treatment of previously untreated chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL).
- Acalabrutinib for MCL: Approval was received for acalabrutinib in combination with bendamustine and rituximab for adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant (ASCT).
- Trastuzumab Deruxtecan: Regulatory approval was obtained for trastuzumab deruxtecan combined with pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast cancer.
In terms of strategic initiatives, AstraZeneca Pharma India Limited launched several programs aimed at advancing healthcare care across the country:
- AI-enabled Lung Cancer Screening: The company signed an MoU with the Government of Telangana to introduce AI-enabled lung cancer screening in public healthcare facilities. This initiative involves facilitating the deployment of Qure.ai's AI-powered chest X-ray solution across 20 public health facilities, supporting clinicians in identifying high-risk pulmonary nodules.
- K+ Connect: A pan-India multidisciplinary initiative was launched to advance the management of hyperkalaemia among patients living with heart failure and chronic kidney disease, coordinating risk identification and monitoring.
- India Coronary Conquest (ICC) 2026: This clinician-led national PCI challenge in collaboration with STEMI India aims to strengthen evidence-based learning and peer exchange for interventional cardiologists and advance cardiovascular care capabilities.
Recognition and Leadership Commentary
The company garnered several accolades during the reporting period. AstraZeneca Pharma India received the Medical Excellence Award for Rare Disease at the OPPI India Awards 2026, while its Hyperkalaemia & Kidney Care initiative was named Runner-up in Marketing Excellence. Furthermore, it received the Gold Award in the Exceptional Employee Experience category from ETHRWorld Employee Experience Awards 2026.
Bhavana Agrawal, Chief Financial Officer and Director of the company, stated that the 30% growth delivered in the first quarter builds upon a strong track record of consistent double-digit growth over the last five years, reinforcing the commitment to investing strategically for sustainable long-term value creation.
Praveen Rao Akkinepally, Country President and Managing Director of AstraZeneca Pharma India Ltd., added that the momentum reflects the strength of the company’s portfolio and its focus on expanding access to serve more patients in India, underscoring their purpose to push the boundaries of science through life-changing medicines.
ASTRAZEN Stock Price Movement
AstraZeneca Pharma India Limited shares slipped by 1.13% on Monday, closing at ₹8090 after shedding ₹92.50 from the previous session's close. The stock traded a total volume of 47,975 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.